- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01760772
Effect of GLP-1 on Postprandial Lipid Metabolism
January 2, 2013 updated by: David Dalessio
The Role of GLP-1 in Lipid Metabolism in Healthy Subjects and in Subjects After Bariatric Surgery
Individuals with obesity have an increased risk for heart disease and diabetes.
There are current drugs on the market that target the hormone, Glucagon like peptide-1 (GLP-1) to treat diabetes.
The investigators want to determine if targeting this hormone will also help people with high cholesterol and triglycerides.
In this study, the investigators are looking at the role of GLP-1 in healthy subjects and subjects that have had bariatric surgery.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Major consequences of the global pandemic of obesity include cardiovascular disease, type 2 diabetes and dyslipidemia.
The dyslipidemia of obesity commonly consists of fasting hypertriglyceridemia with increased plasma very low-density lipoprotein (VLDL), reduced high-density lipoprotein (HDL) and the presence of small, dense low-density lipoprotein (LDL).
However, more recently, increased secretion of intestinally derived lipoproteins (LPs) has been recognized as contributing to this dyslipidemic profile and postprandial lipemia has been linked to adverse health outcomes.
Glucagon-like peptide-1 (GLP-1), a hormone secreted during meal absorption that plays a key role in the control of plasma glucose has been implicated as a candidate hormone for regulating intestinal lipid metabolism.
Studies in rodents demonstrate that treatment with the GLP-1R agonist; exendin-4 (Ex-4) reduced postprandial chylomicron (CM) production and CM-associated cholesterol and triglyceride (TG).
Similar results were found in Type 2 diabetes (T2D) subjects treated with Ex-4; in these reports there was a reduction in both intestinally derived LP production and total plasma TG.
The objective of this study is to determine whether GLP-1 is involved in the physiologic regulation of postprandial lipid metabolism in healthy women, and to test the hypothesis that the improved lipid parameters found in overweight women who have had bariatric surgery are mediated by GLP-1.
The specific aims for this project will 1) determine if either pharmacologic treatment with GLP-1 and/or antagonism of endogenous GLP-1 activity improves postprandial lipid metabolism in healthy subjects and 2) determine the role of elevated postprandial GLP-1 levels on lipid metabolism in obese subjects who have had a sleeve gastrectomy.
The investigators will use infusions of synthetic GLP-1 with the native hormone to confirm the lipid-lowering results that have been published using pharmacologic GLP-1 receptor (GLP-1R) agonists.
The investigators will also use the GLP-1R antagonist exendin-(9-39) to determine the role of endogenous GLP-1 on lipemia after a test meal.
A demonstration that this is a physiologic action would expand the current understanding of lipid metabolism, provide new insight into the effects of bariatric surgery, and allow the design of more refined, mechanistic studies of this process.
In addition, the potential for GLP-1R signaling to promote lipid metabolism has direct translational importance in that therapies already exist that could capitalize on this mechanism.
Understanding the role of GLP-1R regulation of lipid absorption and clearance could lead to more appropriate targeting of GLP-1 based drugs to specific diabetic patients, i.e. ones with problematic dyslipidemia and higher risk for cardiovascular disease.
Moreover, understanding the effects of GLP-1 on plasma lipids could eventually lead to new approaches for treating nondiabetic dyslipidemic persons.
Study Type
Interventional
Enrollment (Anticipated)
42
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michelle R Adams, PhD
- Phone Number: 513-558-6920
- Email: michelle.adams@uc.edu
Study Contact Backup
- Name: David D'Alessio, MD
- Phone Number: 513-558-6689
- Email: DALESSD@UCMAIL.UC.EDU
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220
- Veteran's Affairs Clinical Research Unit
-
Contact:
- Michelle R Adams, PhD
- Phone Number: 513-558-6920
- Email: michelle.adams@uc.edu
-
Principal Investigator:
- Michelle R Adams, PhD
-
Principal Investigator:
- David D'Alessio, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aim 1: Healthy, normolipemic men and postmenopausal women; aged 40-60 years; BMI between 25-35
- Aim 2: Men and postmenopausal women after successful vertical sleeve gastrectomy (VSG) surgery and age- and weight-matched non-surgical control men and postmenopausal women; ages between 40-6- years; BMI between 28-35; steady weight for at least 3 months prior to study
Exclusion Criteria:
Exclusion Criteria for Aim 1:
- History or clinical evidence of impaired fasting glucose or diabetes mellitus, myocardial infarction or symptoms of congestive heart failure, history or active liver or renal disease, calculated glomerular filtration rate < 60 mL/min).
- History of extreme dyslipidemia (i.e. familial hypercholesterolemia) or Cardiovascular disease (CVD).
- Fasting plasma total cholesterol > 200 mg/dL and fasting plasma TGs > 150 mg/dL.
- Surgery within 6 months.
- Pregnancy or lactation.
- Anemia defined as hematocrit < 33%.
- History of cancer or anorexia nervosa or GI disorders.
- Use of medications that alter insulin sensitivity (i.e. niacin, glucocorticoids, metformin) or lipid metabolism (i.e. statin, niacin, fibrate, ezetimibe).
- Plasma HbA1c > 6.0.
- Fasting glucose > 110 mg/dL
- Electrocardiogram (ECG) abnormalities: evidence of ischemia or arrhythmia.
Exclusion Criteria for Aim 2:
- History of CVD.
- Fasting plasma total cholesterol > 250 mg/dL and fasting plasma TGs > 300 mg/dL.
- Surgical intervention within 6 months.
- Anemia defined as hematocrit < 33%.
- History of cancer or anorexia nervosa or other major GI disease or surgery.
- Use of medications that alter insulin sensitivity (i.e. niacin, glucocorticoids, metformin) or lipid metabolism (i.e. statin, ezetimibe).
- HbA1c > 6.0.
- Fasting glucose > 110 mg/dL
- Electrocardiogram (ECG) abnormalities: evidence of ischemia or arrhythmia.
- Significant renal, hepatic or pulmonary disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Saline
0.9% saline
|
Constant infusion
|
Experimental: Exendin-9 (Ex-9)
Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min
|
Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
Other Names:
|
Experimental: GLP-1
GLP-1 infusion at 0.3 pmol/kg/min
|
Constant infusion of GLP-1 at 0.3 pmol/kg/min
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postprandial Lipids Levels and Apolipoprotein B (ApoB) Levels in plasma
Time Frame: 2 years
|
Total and lipoprotein-associated triglyceride and cholesterol levels in baseline and postprandial plasma. Total apolipoprotein B48 (ApoB48) and apolipoprotein B100 (ApoB100) levels in baseline and postprandial plasma. |
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma insulin and glucagon
Time Frame: 2 years
|
Plasma insulin and glucagon in the fasting and postprandial periods
|
2 years
|
Plasma free fatty acid (FFA) and glucose levels
Time Frame: 2 years
|
Plasma FFA and glucose levels during the fasting and postprandial state
|
2 years
|
Plasma d-xylose and acetaminophen levels
Time Frame: 2 years
|
Plasma d-xylose and acetaminophen levels as indices of gastric emptying
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michelle R Adams, PhD, University of Cincinnati
- Principal Investigator: David D'Alessio, MD, University of Cincinnati
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Anticipated)
February 1, 2015
Study Completion (Anticipated)
February 1, 2015
Study Registration Dates
First Submitted
November 17, 2012
First Submitted That Met QC Criteria
January 2, 2013
First Posted (Estimate)
January 4, 2013
Study Record Updates
Last Update Posted (Estimate)
January 4, 2013
Last Update Submitted That Met QC Criteria
January 2, 2013
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-09-20-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Disease
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Yonsei UniversityCompletedMitral Valvular Heart Disease
-
University of PennsylvaniaCompleted
-
Abbott Medical DevicesRecruitingAortic Valve Disease | Valvular Heart DiseaseChina
-
Mansoura UniversitySuspendedValve Heart Disease | Elective Cesarean DeliveryEgypt
-
Tulane UniversityCompletedCardiomyopathies | Valvular Heart Disease | Pericardial DiseaseUnited States
-
Assiut UniversityCompleted
-
InnovHeartActive, not recruitingHeart Valve Diseases | Mitral Regurgitation | Valve Heart Disease | Mitral Valve Disease | Mitral DiseaseLithuania, Denmark, Hungary
-
Aarhus University Hospital SkejbyInstitute for Clinical and Experimental MedicineCompletedHeart Failure | Coronary Heart Disease | Ischemic Heart DiseasesDenmark
-
Fundació Institut de Recerca de l'Hospital de la...UnknownValvular Heart Disease | Cardiac Disease | Nurse's Role | CompetenceSpain
Clinical Trials on saline
-
Vanderbilt University Medical CenterActive, not recruitingPostural Tachycardia SyndromeUnited States
-
Johns Hopkins UniversityCystic Fibrosis FoundationCompletedCystic Fibrosis
-
University Hospital Inselspital, BerneCompletedCardiovascular Diseases | Valvular Heart DiseaseSwitzerland
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Dr. Michael FlavinWithdrawn
-
Imam Abdulrahman Bin Faisal UniversityUnknownOtorhinolaryngologic Diseases | RhinosinusitisSaudi Arabia
-
Szpital im. Św. Jadwigi ŚląskiejRecruiting
-
Makassed General HospitalCompletedLength of Hospital StayLebanon
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia
-
University of Washington, the Collaborative Health...Cystic Fibrosis FoundationCompleted